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Background
Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy
syndrome) is an autosomal recessive lysosomal storage
disorder determined by mutations in the arylsulfatase B
gene located in chromosome 5. Pathogenic mutations of
this gene result in reduced or absent activity of enzyme
arylsulfatase B (N-acetylgalactosamine 4-sulfatase,
ARSB). Incomplete degradation and cellular accumula-
tion of glycosaminoglycans (dermatan sulfate) result in
cell and tissue injury following clinical manifestation.
Three major clinical phenotypes of the disease could be
distinguished among our patients: severe, and intermedi-
ate. Because patients with an attenuated MPS VI pheno-
type present with disease symptoms late in life, it is
highly probable that they may be remain under diag-
nosed and/or misdiagnosed.
Objectives
The aim of the study was to describe the natural clinical
course and present abnormality in movement system in
patients with attenuated Maroteaux-Lamy syndrome
ever diagnosed in Poland, Belarus and Baltic States
(Lithuania, Estonia).
Methods
Patients with attenuated phenotype MPS VI (n=9) were
identified by retrieving the data from the registries of
t h ef i v ed i a g n o s t i cc e n t e r sf o rM P SV Ii nC e n t r a la n d
Eastern Europe. In all patients, clinical diagnosis was
biochemically confirmed by demonstrating abnormal
excretion of dermatan sulfate in urine and deficient
activity of ARSB in leukocytes and/or cultured skin
fibroblasts. Musculoskeletal system was evaluated in all
the patients
Results
For patients with attenuated MPS VI disease (n = 9),
mean age at diagnosis was 22 years (range 13 -37 years,
median 22 years). In these patients height was only
slightly decreased and MPS VI features developed later in
the course of the disease (mean age at the onset of symp-
toms was 8.7 years; range 2-21 years, median 7 years).
Over 88% of these patients showed first signs of the dis-
ease after the age of 5 years, in some cases at the age of
8, 12 or even 21 years. The mean of delay in diagnosis
was 13 years (range 8 - 23 years, median 9 years).
Musculoskeletal system was evaluated in all the
patients. All patients showed musculoskeletal symptoms
such as impaired mobility - 2 (22%) patients, joint stiff-
ness - all patients (100%), joint contractures - all
patients (100%), spinal deformity: all patients (100%),
carpal tunnel syndrome -6 patients (67%), one patient
has osteoporosis and arthrosis of hip joints.
Conclusions
Because patients with musculoskeletal symptoms in the
early stages of the disease are often diagnosed by rheu-
matologists, it is important to consider lysosomal sto-
rage disorders in differential diagnosis. Early diagnosis
of MPS VI is essential to begin enzyme replacement
therapy early and to prevent or improve clinical signs.
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